QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alarcon, C M Articles by Heitman, J Search for Related Content PubMed PubMed Citation Articles by Alarcon, C M Articles by Heitman, J Social Bookmarking                   What's this?

Research Papers

Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.

Department of Genetics, Duke University Medical Center, Durham, North Carolina 27710 USA.

Abstract

In complex with the prolyl isomerase FKBP12, the natural product rapamycin blocks signal transduction in organisms as diverse as yeast and man. The yeast targets of FKBP12-rapamycin, TOR1 and TOR2, are large proteins with homology to lipid and protein kinases. A mammalian FKBP12-rapamycin binding protein, RAFT1, shares 39% and 43% identity with TOR1 and TOR2 proteins, respectively but has not been linked to rapamycin action in vivo. We find that when expressed in yeast, neither wild-type nor mutant RAFT1 complemented tor mutations or conferred rapamycin resistance. In contrast, TOR1-RAFT1 and TOR1-RAFT1 hybrid proteins containing the carboxy-terminal RAFT1 kinase domain complemented tor2 and tor1 mutant strains, respectively. Moreover, TOR2-RAFT1 and TOR1-RAFT1 hybrid proteins mutated at the position corresponding to rapamycin-resistant TOR mutants (S20351) conferred rapamycin resistance. Like the TOR2 protein, the TOR2-RAFT1 proteins were stably expressed, localized to the vacuolar surface, and associated with a phosphatidylinositol-4 kinase activity. These findings directly link the mammalian TOR homolog RAFT1 to rapamycin action in vivo and indicate that the TOR/RAFT1 kinase domain has been functionally conserved from yeast to man.

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. Puria, S. A. Zurita-Martinez, and M. E. Cardenas From the Cover: Nuclear translocation of Gln3 in response to nutrient signals requires Golgi-to-endosome trafficking in Saccharomyces cerevisiae PNAS, May 20, 2008; 105(20): 7194 - 7199. [Abstract] [Full Text] [PDF]

				S. A. Zurita-Martinez, R. Puria, X. Pan, J. D. Boeke, and M. E. Cardenas Efficient Tor Signaling Requires a Functional Class C Vps Protein Complex in Saccharomyces cerevisiae Genetics, August 1, 2007; 176(4): 2139 - 2150. [Abstract] [Full Text] [PDF]

				A. Reinke, S. Anderson, J. M. McCaffery, J. Yates III, S. Aronova, S. Chu, S. Fairclough, C. Iverson, K. P. Wedaman, and T. Powers TOR Complex 1 Includes a Novel Component, Tco89p (YPL180w), and Cooperates with Ssd1p to Maintain Cellular Integrity in Saccharomyces cerevisiae J. Biol. Chem., April 9, 2004; 279(15): 14752 - 14762. [Abstract] [Full Text] [PDF]

				J. L. Nitiss A copper connection to the uptake of platinum anticancer drugs PNAS, October 29, 2002; 99(22): 13963 - 13965. [Full Text] [PDF]

				N. S. Cutler, X. Pan, J. Heitman, and M. E. Cardenas The TOR Signal Transduction Cascade Controls Cellular Differentiation in Response to Nutrients Mol. Biol. Cell, December 1, 2001; 12(12): 4103 - 4113. [Abstract] [Full Text] [PDF]

				M. C. Cruz, A. L. Goldstein, J. Blankenship, M. Del Poeta, J. R. Perfect, J. H. McCusker, Y. L. Bennani, M. E. Cardenas, and J. Heitman Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3162 - 3170. [Abstract] [Full Text] [PDF]

				M. E. Cardenas, N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman The TOR signaling cascade regulates gene expression in response to nutrients Genes & Dev., December 15, 1999; 13(24): 3271 - 3279. [Abstract] [Full Text]

				M. E. Cardenas, M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action Clin. Microbiol. Rev., October 1, 1999; 12(4): 583 - 611. [Abstract] [Full Text] [PDF]

				C. M. Alarcon, J. Heitman, and M. E. Cardenas Protein Kinase Activity and Identification of a Toxic Effector Domain of the Target of Rapamycin TOR Proteins in Yeast Mol. Biol. Cell, August 1, 1999; 10(8): 2531 - 2546. [Abstract] [Full Text]

				M. C. Cruz, L. M. Cavallo, J. M. Gorlach, G. Cox, J. R. Perfect, M. E. Cardenas, and J. Heitman Rapamycin Antifungal Action Is Mediated via Conserved Complexes with FKBP12 and TOR Kinase Homologs in Cryptococcus neoformans Mol. Cell. Biol., June 1, 1999; 19(6): 4101 - 4112. [Abstract] [Full Text] [PDF]

				D. Zaragoza, A. Ghavidel, J. Heitman, and M. C. Schultz Rapamycin Induces the G0 Program of Transcriptional Repression in Yeast by Interfering with the TOR Signaling Pathway Mol. Cell. Biol., August 1, 1998; 18(8): 4463 - 4470. [Abstract] [Full Text]

				K. K. Jacob, J. Sap, and F. M. Stanley Receptor-like Protein-tyrosine Phosphatase alpha  Specifically Inhibits Insulin-increased Prolactin Gene Expression J. Biol. Chem., February 20, 1998; 273(8): 4800 - 4809. [Abstract] [Full Text] [PDF]

				K. Hara, K. Yonezawa, M. T. Kozlowski, T. Sugimoto, K. Andrabi, Q.-P. Weng, M. Kasuga, I. Nishimoto, and J. Avruch Regulation of eIF-4E BP1 Phosphorylation by mTOR J. Biol. Chem., October 17, 1997; 272(42): 26457 - 26463. [Abstract] [Full Text] [PDF]

				J. Rohde, J. Heitman, and M. E. Cardenas The TOR Kinases Link Nutrient Sensing to Cell Growth J. Biol. Chem., March 23, 2001; 276(13): 9583 - 9586. [Abstract] [Full Text] [PDF]